E

Molecular Jiu-Jitsu – Turning Cancer’s Mistakes Against Itself

Our 7th AACR Preview takes stock of an emerging class of anti-cancer agents

March 18, 2024
E

Precision Targeting of Elusive Cancer Oncogenes

More gems from the TARGETS23 poster halls

October 16, 2023
E

How to Knock Out Cancer’s Backup Plan

Searching for well tolerated combinations in the KRAS niche

October 13, 2023
E

The Next Frontier

From small acorns, so oak trees grow

October 12, 2023
E

What to watch out for at TARGETS23 – Part 2

What to watch out for in DDR, epigenetic therapies, and other hot topics

October 11, 2023
E

Ever Decreasing Circles

From epigenetics to SHP2, a look at various upcoming presentations this month

October 5, 2023
E

Early stage oncology data of interest in TARGETS23 preview

A look at some hot topics from the TARGETS/TRIPLE meeting in Boston

September 20, 2023
E

Exciting new developments in the KRAS space

What started out as a short update from the recent EORTC-NCI-AACR (ENA / Triple Meeting) in Barcelona on…

November 2, 2022
E

The art and science of a novel immunotherapy for solid tumours

Reprogramming T cell phenotype is becoming a hot topic in solid tumours and here's why...

October 28, 2022
E

Targeting MYC – trick or treat?

Beyond KRAS - targeting another of the four horsemen of the apocalypse

October 25, 2022
E

Endless DDR changes and how we are going beyond PARP inhibitors

A detailed look at Repare's ATR inhibitor data from the TRIPLE meeting

October 15, 2021
E

New directions in drugging KRAS

Where next in the ever expanding KRAS runners and riders?

October 11, 2021
E

A look at Relay’s surgical approach to FGFR inhibition

Will Relay's FGFR2 live up to expectations?

October 8, 2021
E

Slicing the salami

It’s time to look at progress on the ADC front, something we sporadically cover where there are new…

October 8, 2021
E

Spotting the wood from the trees

What can we learn from KRASi combinations? Do any stand out?

October 7, 2021
E

Moving On Up

We still need to kill cancer cells to get durable complete responses - a look at ways to accomplish this feat

October 29, 2020
E

Buildings walls versus building cathedrals

The devil is in the finer details...

October 27, 2020
E

What can we learn from Mirati’s adagrasib in lung and other cancers?

It’s time to look at the latest update on KRAS mutation specific agents in clinical development as…

October 25, 2020
E

TRIPLE highlights and lowlights in Developmental Therapeutics

The trials and tribulations of targeted agents in developmental therapeutics

October 25, 2020
E

When oncology and coronavirus worlds collide

Key RNA transcription factors may have a role to play as therapeutic targets for both cancer treatment and the coronavirus

March 4, 2020
E

A look at Mirati in the context of the broader KRAS niche

An interview with Mirati's Chuck Baum and Jamie Christensen exploring the evolving opportunities and challenges in the KRAS G12C niche

February 25, 2020
E

A hidden gem in the KRAS niche

Monotherapy approaches won't be enough to shut down KRAS mutations in solid tumours, so what targets can we add in to reduce acquired resistance?

February 19, 2020
E

The Future of Oncology R&D

Six key strategic factors to consider going forward in the quest for future oncology R&D pipelines

January 6, 2020
E

Update on the KRAS Runners and Riders

A look at new developments in the KRAS niche and also a potential emerging novel target in addressing the development of acquired resistance.

December 3, 2019
E

Insights on targeting the oncogene SHP2

How do we improve responses to EGFR, BRAF & KRAS inhibitors? One way may be add in a SHP2 inhibitor - we look at why this target matters and which competitors are in this niche.

October 30, 2019
E

New path to market opportunity for Kura in SCCHN

KRAS isn't the only RAS mutation seeing progress - there's also HRAS which is now druggable thanks to Kura Oncology's tipifarnib

October 29, 2019
E

What do we learn from a first look at Mirati’s KRAS G12C inhibitor MRTX849?

Dr Pasi Janne presented the initial first-in-man data from Mirati's KRAS G12C inhibitor MRTX849 - what did we learn?

October 28, 2019
E

Targeting NRG1 Gene Fusions

What did we learn at #Targets19 about targeting NRG1 gene fusions with MCLA-128?

October 27, 2019
E

Further issues surrounding RAS inhibition in oncology

On dosing issues, read across from BRAF in CRC, what is SOS1 and a look at future combinations...

October 25, 2019
E

A novel approach to targeting BRAF and KRAS mutant cancers

How do we go about targeting KRAS mutations beyond G12C? Here's one elegant way that is promising yet very early in which it could be approached...

October 23, 2019
E

Can STING agonists promote cancer metastasis?

Can STING agonists promote cancer metastasis in some patients? That's one of the key questions from new research linking chromosomal instability with tumor metastasis through activation of the cGAS-STING pathway.

January 23, 2018
E

What can genomics and tumours teach us about cancer drug development?

A look at loss of heterozygosity and what it means for new lung cancer therapies

November 20, 2017
E

TARGETS17 Gems from the Poster Halls

A look at new targets, molecules and approaches to cancer research from #TARGETS17 in Philly

November 7, 2017
E

Some simply stunning cancer research for Journal Club

Science Fridays: A look at six key studies recently published on cancer research that BSB readers can learn from.

November 3, 2017
E

Key Highlights from Day 3 at AACR-NCI-EORTC TARGETS17

Highlights from Day 3 of the AACR-NCI-EORTC Molecular Targets meeting in Philadelphia

October 29, 2017
E

Highlights from Day 2 AACR-NCI-EORTC #TARGETS17

A look at some of the important data coming out of Day 2 of #Targets17 in Philadelphia

October 28, 2017
E

Key Highlights From AACR Molecular Targets Day 1

Commentary on Day 1 of 2017 AACR NCI EORTC Molecular Targets and Cancer Therapeutics Conference in Philadelphia

October 27, 2017
E

Blueprint Shows Promise in GIST and HCC

Targeted therapies aren't dead yet - oncogenic drivers are still important in many cancers. Here we look at progress in GIST, systemic mastocytosis and HCC...

February 16, 2017
E

How to improve response rates with targeted therapies in oncology

Exploring clinical trials with targeted therapies, including PARP and ATR inhibitors and combination approaches

February 2, 2017
E

A manifesto for immuno-oncology research

A draft manifesto for IO in cancer research and what we need to learn

February 1, 2017
E

ASH16 Update on BCMA CAR T cell therapies

A look at the new various developments in CAR Therapies targeting BCMA in multiple myeloma

December 14, 2016
E

Gems from the Poster Halls at EORTC-NCI-AACR in Munich

Gems from the Poster Hall on Wednesday at EORTC-NCI-AACR Molecular Targets meeting in Munich

November 30, 2016
E

Making breast cancer cells become normal again

Can we revert the mutant phenotype in breast cancer and return to a normal, non cancerous phenotype?

November 30, 2016
E

ENA 2016 Immunotherapy Symposium Highlights

Highlights from the Charles River Immunotherapy Symposium in Munich, 2016

November 29, 2016
E

AstraZeneca’s AZD9291 osimertinib is approved as Tagrisso

AstraZeneca's AZD9291 was approved by the FDA in EGFR T90M mutation positive lung cancer today and is now known as osimertinib or Tagrisso.

November 13, 2015
E

What’s Hot at AACR #Targets15 in Boston?

Preview of the key topics coming up at the AACR-NCI-EORTC Molecular Targets meeting in Boston, including Pasi Janne's interesting data on T790M negative NSCLC...

October 27, 2015
E

Potential of Rociletinib in T790M negative NSCLC

Clovis have observed responses in T790M positive AND negative lung cancer with rociletinib - implications for the commercial opportunity are discussed in this post.

January 28, 2015
E

UCL Drives CD19 CAR T Cell Therapy Forward in Europe

University College London (UCL) is leading the way in European clinical trials of CAR T Cell therapies that target CD19.

April 14, 2015
E

EORTC Molecular Targets – new developments in Ovarian Cancer

Ovarian cancer has lagged behind other solid tumours in terms of development, but this situation may soon change with promising new agents being developed

November 19, 2014
E

Rociletinib versus AZD9291 race to market heats up in T790M lung cancer at EORTC

Clovis present their Phase 2 data with the new rociletinib formulation at EORTC-AACR-NCI in Barcelona

November 19, 2014
E

Agios IDH1 Inhibitor AG-120 shows promise in AML $AGIO

Agios AG-120 IDH1 Inhibitor shows promise in acute myeloid leukemia (AML) according to data to be presented at the EORTC-AACR-NCI Molecular Targets and Cancer Therapeutics Symposium in Barcelona

November 18, 2014
E

Update on overcoming resistance in metastatic melanoma

What new clinical approaches are being investigated to overcome resistance in melanoma?

March 20, 2014
E

CDK inhibitors: will palbociclib and LEE011 make it to market in breast cancer?

Cell cycle inhibitors have been shown to have utility in cancer treatment. A new subclass is emerging to target CDK4/6 with more specificity and less toxicity.

March 19, 2014
E

The future of cancer research – Part 2

The huge wealth of research at the AACR-NCI-EORTC Boston conference provided a great learning environment of where future research with TKIs is likely to be heading...

November 6, 2013
E

The future of cancer research – what I learned from the AACR Targets meeting Part 1

The cancer landscape is rapidly changing, in more ways than people realise. Diagnostics are also of increasing importance in helping to decide which therapies patients should receive to optimize treatment.

November 5, 2013
E
Dr Deepak Sampath, Genentech

Gazyva and ABT-199 in CLL & NHL – an interview with Genentech’s Deepak Sampath

An interview with Dr Deepak Sampath from Genentech on the rational for combining obinutuzumab (GA101) with GDC-0199 (ABT-199) for the treatment of B-cell hematological malignancies such as CLL & non Hodgkin’s lymphoma (NHL).

November 1, 2013
E

New insights on checkpoint inhibitors and CART in CLL and solid tumors

An update on checkpoint inhibitors and CART from the AACR-NCI-EORTC Molecular Targets meeting - a lot of exciting possibilities are emerging!

October 25, 2013
E

Abraxane kills potential of MLN0264 in pancreatic cancer

Following the FDA approval of Abraxane, MLN0264, a novel ADC targeting GCC, may no longer have potential as a therapeutic in pancreatic cancer.

October 21, 2013
E

Cerulean CRLX101 Challenges and Opportunities

Cerulean are developing a novel nanopharmaceutical that targets HIF1-alpha and is synergistic with anti-angiogenic drugs for RCC and Ovarian cancers.

October 21, 2013
E

AstraZeneca ramps up AZD9291 lung cancer clinical development

At the AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics conference, Susan Galbraith, M.D, Ph.D. Head of the Oncology Innovative Medicines Unit at AstraZeneca discussed the rapid development of AZD9291, a potent and selective third-generation EGFR inhibitor.

October 20, 2013
E

Pfizer next gen ALK inhibitor PF-06463922 could replace Xalkori

Preclinical data for PF-06463922 (Pfizer), a next generation ALK inhibitor, with potency for all known Crizotinib ALK resistant mutants and ability to cross the blood brain barrier was presented today at the 2013 International Conference on Molecular Targets and Cancer Therapeutics in Boston.

October 20, 2013
E

A quick preview of the AACR Molecular Targets Conference

Preview of some of the interesting non-embargoed abstracts from the ACCR-NCI-EORTC Molecular Targets conference in Boston

October 15, 2013
E
Cambridge from Bay Bay Boston

Preview of 2013 AACR Molecular Targets Conference in Boston

Preview of 2013 AACR-EORTC-NCI Molecular Targets and Cancer Therapeutics Conference in Boston. This is a "must attend" meeting for anyone interested in cancer drug development.

October 11, 2013